Why the most promising medicines are the hardest to deliver
The molecules driving the biggest advances in medicine are also the ones our delivery tools handle worst. The bottleneck is rarely the discovery. It is getting the molecule to the right place, intact.
For most of the last century, medicine ran on small molecules: compact, sturdy chemicals that could be swallowed as a pill and shrug off heat, acid and time. The molecules defining the next century are different. Proteins, peptides and RNA are larger, more precise and more potent. They can do things small molecules never could. They are also fragile, and that fragility runs headlong into the way we deliver drugs today.
Three walls, one problem
A large molecule that works in a dish has to clear three obstacles before it works in a person. Each one is enough to stop a promising therapy on its own.
- Penetration. Big molecules struggle to cross skin or reach solid tissue. The most valuable actives are often the ones conventional carriers leave stranded on the surface.
- Stability. Many actives oxidize or break down within weeks at room temperature. That forces a cold chain, which adds cost and limits where a therapy can realistically go.
- Exposure. Delivering to one place without dosing the whole body is unsolved for most large molecules. Systemic reach means systemic risk.
Why the gap keeps widening
Discovery has raced ahead. We can now design proteins, peptides and genetic medicines with remarkable specificity. Delivery has not kept pace, so the list of molecules that are scientifically ready but practically undeliverable keeps growing. The cost of that gap is measured in therapies that never reach patients, not because they do not work, but because they cannot arrive.
Delivery is the unlock
That inversion is also the opportunity. If the science of the molecule is no longer the limiting step, then whoever solves delivery unlocks the value trapped behind it, across many molecules at once rather than one at a time. That is the layer reThink64 builds: the enabling delivery technology that gets large molecules stable, into tissue, and concentrated where they are meant to act.